RxDoctor Payments Data

Gaurav Tandon, MD

Nephrology · Jacksonville, FLNPI 1306069562

Payments from drug & device makers

$1,136in general payments, 2019–2025

Across 48 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$193
  • Bayer$130
  • Boston Scientific$125
  • Otsuka America Pharmaceutical, Inc.$124
  • Novartis$105
  • Boehringer Ingelheim$82
  • plus $376 from 8 others

What the payments were for

  • Food & beverage$1,12099%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,136 in reported general payments places this provider in the 40th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$557,098
Medicare patients
786
Services billed
6,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol107$83,840
VelphoroSucroferric Oxyhydroxide18$47,694
JardianceEmpagliflozin55$37,970
EntrestoSacubitril/Valsartan18$19,730
LokelmaSodium Zirconium Cyclosilicate16$16,215
EliquisApixaban21$11,931
Sevelamer Carbonate41$10,905
ClinolipidFat Emulsion/Olive/Soy/Phospho49$7,244
ClinisolParenteral Amino Acid 15% No.530$3,947
Cinacalcet Hcl34$2,456
Losartan Potassium342$2,442
Calcitriol116$2,325
Doxazosin Mesylate148$1,339
Midodrine Hcl20$1,246
Tamsulosin Hcl130$1,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$193$100,055123 claims
Fresenius USA Marketing, Inc.Velphoro$35$47,69418 claims
Boehringer IngelheimJardiance$82$37,97055 claims
NovartisEntresto$105$19,73018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 756 nephrology providers in Florida.

Other nephrology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →